Date published: 2026-8-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

Nucling CRISPR/Cas9 KO Plasmid (h): sc-406671

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • Nucling CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Nucling genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • Nucling HDR Plasmid (h) (sc-406671-HDR) is recommended for co-transfection with Nucling CRISPR/Cas9 KO Plasmid (h) to enable selection of successfully edited cells through HDR-mediated integration of a puromycin resistance cassette and RFP reporter gene
  • Nucling HDR Plasmid (h) is a pool of plasmids, each containing a homology-directed repair (HDR) template corresponding to the gRNA target sites in the Nucling CRISPR/Cas9 KO Plasmid (h)
  • Each HDR plasmid contains two ~800 bp homology arms flanking the puromycin resistance and RFP cassettes, designed to bind genomic DNA sequences surrounding the Cas9-induced double-strand break site and facilitate precise HDR-mediated integration
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
  • Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Nucling Antibody (A-5): sc-515005
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    Nucling CRISPR/Cas9 KO Plasmid (h)

    sc-406671
    20 µg
    $397.00

    Nucling HDR Plasmid (h)

    sc-406671-HDR
    20 µg
    $445.00

    Overview

    UACA encodes Nucling, a nuclear protein implicated in the regulation of apoptosis and stress-responsive transcriptional programs. Nucling has been reported to influence NF-κB signaling dynamics and can modulate expression of pro- and anti-apoptotic genes, linking it to cellular decisions governing survival, inflammation, and DNA damage responses. Altered UACA/Nucling expression has been observed in multiple cancer and immune-related contexts, where dysregulated apoptosis and NF-κB pathway activity contribute to disease-associated phenotypes. These features make UACA a useful target for mechanistic studies of cell fate regulation, transcriptional control, and pathway crosstalk in human model systems.

    Nucling CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UACA gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the UACA locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.

    When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.

    Homology-Directed Repair (HDR) Donor — Puromycin Cassette with RFP Reporter

    For applications requiring confirmed, selectable knockout clones, Nucling HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined UACA target site.
    When co-transfected with Nucling CRISPR/Cas9 KO Plasmid (h):

    • The PuroR-RFP cassette integrates at the Cas9 cut site via HDR, disrupting the UACA open reading frame.
    • RFP fluorescence provides an immediate visual indicator of successful integration, enabling fluorescence-based identification or sorting of edited cells prior to or alongside puromycin selection.
    • Successfully edited cells are confirmed through puromycin resistance, substantially reducing clone screening burden.
    • This selection strategy is ideal for generating stable, clonal KO cell lines for downstream functional studies, drug screening, or model development.

    Cre-lox Cassette Removal System

    The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the UACA locus and eliminating potential confounding effects on downstream assays.
    This two-step approach:

    • Minimizes disruption to local chromatin architecture and neighboring regulatory elements
    • Restores a near-native genomic context at the edited locus
    • Enables reuse of the puromycin selection strategy in the same cell line for additional edits

    Key Features

    • gRNA targeting UACA exon(s) critical for Nucling function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • HDR donor with puromycin resistance for positive clone selection
    • loxP-flanked PuroR cassette with Cre recombinase vector for seamless marker removal
    • Supplied ready to use for delivery by transfection

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.